Pfizer Agrees to Invest US$300 Mln in Joint R&D With S. Korea (South Korea)
This article was originally published in PharmAsia News
Executive Summary
Pfizer has signed a preliminary deal with South Korea's government to invest $300 million in joint drug research and development, from animal testing to clinical research projects, over the next five years. The research will be conducted at various local centers in South Korea through 2012. If finalized, Pfizer's deal will make it the single largest research-and-development foreign investor in South Korea. (Click here for more
You may also be interested in...
Pfizer Korea Signs Development Pact With State KRIBB For Liver and Gastric Cancer Drugs
SEOUL - Two years after signing a memorandum of understanding on cooperation, Pfizer and Korea's state-run Korea Research Institute for Bioscience and Biotechnology signed a more formal agreement May 18 to start collaborative research work for joint development of drugs for liver and gastric cancer
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.